![NICE logo](/sites/default/files/styles/square_card_l/public/media/images/media-2515.jpg.webp?itok=fsPZhxtT)
Acalabrutinib approved for NHS treatment of CLL in England and Wales
NICE has approved acalabrutinib for NHS use for some people with CLL.
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
NICE has approved acalabrutinib for NHS use for some people with CLL.
Plotting a route out of the pandemic and towards world-leading cancer services.
Talking about the BBC article on the COVID-19 vaccine and people affected by cancer.
Research participants needed for study of lung cancer screening decision-making after Hodgkin lymphoma.
NICE is not recommending mogamulizumab for the treatment of relapsed or refractory mycosis fungoides or Sézary syndrome.
Our new book entitled When someone close to you has lymphoma is now available.
Listen to sisters Sarah Standing and Emma Forbes talk about supporting each other when they couldn’t be together.
'It's A Sin' really highlights how much treatments have moved on since the 1980s.
Results of the ZUMA-5 trial show that CAR T-cell therapy has high response rates in relapsed or refractory follicular lymphoma or marginal zone lymphoma.
Thursday 4 February is World Cancer Day, an international day to raise awareness and understanding of all types of cancer, including lymphoma. It is also Time to Talk Day, that encourages everyone across the UK to talk about mental health and wellbeing.